Like its portfolio companies, Horizon Technology Finance is opportunistic and forward-looking. Taking the long view does more than bridge the financial gap. It allows Horizon’s portfolio companies to get from where they are to where they want to be.
Horizon offers not only the capital a company needs to grow, but a deep understanding of the technology and life science markets, strong relationships in the venture debt and capital industries, a proven financing model and years of experience helping companies and their investors succeed.
Horizon realizes that the success of its portfolio companies is not solely dependent on financing alone. An understanding of their unique growth patterns, along with Horizon’s deep relationships in the venture world, and proven experience getting deals done combine to bring more than just capital to the table.
Horizon leverages its experience, flexibility, financial rigor and optimism to help advance new technologies and build market leading companies. Horizon's team has provided more than $1 billion in venture debt since 2004.
“The venture lending experts at Horizon created a flexible financing solution that greatly strengthens our future growth prospects.”
Gordon MeyerPresident and CEO of eBureau
“This attractive loan facility, led by Horizon’s experienced team of venture lending professionals, provides us with a critical source of capital necessary for NinePoint’s future growth.”
Dr. Christopher von JakoPresident and CEO of NinePoint Medical
“By providing our company with a customized financing solution that meets our immediate capital needs … Horizon demonstrated its knowledge and experience as a leading venture lender to the healthcare and technology industries.”
Irv LichtenwaldPresident and CEO of Medsphere
“Having the right capital at the right time is critical for a growth stage company. Horizon’s flexible financing solution, team of venture lending experts, and smooth and efficient loan closing have provided Interleukin with the strategic capital necessary for its continued growth.”
Dr. Kenneth KornmanCEO of Interleukin Genetics
“With Horizon’s attractive growth capital we are well positioned to add value for our current customers while marketing our best in class products to prospective organizations.”